Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy

Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype

(2016) Marie Kostine et al.   MODERN PATHOLOGY

Targetless T cells in cancer immunotherapy

(2016) Per thor Straten et al.   Journal for ImmunoTherapy of Cancer

Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma

(2016) Pratistha Koirala et al.   Scientific Reports

FoxP3+ and IL-17+ cells are correlated with improved prognosis in cervical adenocarcinoma

(2015) Simone Punt et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D–NKG2DL dependent manner

(2015) L. Fernández et al.   CANCER LETTERS

New Strategies in Sarcoma: Linking Genomic and Immunotherapy Approaches to Molecular Subtype

(2015) J. Lim et al.   CLINICAL CANCER RESEARCH

Enhanced T-Cell Immunity to Osteosarcoma Through Antibody Blockade of PD-1/PD-L1 Interactions

(2015) Danielle M. Lussier et al.   JOURNAL OF IMMUNOTHERAPY

A Sleeping Beauty forward genetic screen identifies new genes and pathways driving osteosarcoma development and metastasis

(2015) Branden S Moriarity et al.   NATURE GENETICS

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neoantigens in cancer immunotherapy

(2015) T. N. Schumacher et al.   SCIENCE

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy

(2015) W. Peng et al.   Cancer Discovery

Unscrambling the genomic chaos of osteosarcoma reveals extensive transcript fusion, recurrent rearrangements and frequent novel TP53 aberrations

(2015) Susanne Lorenz et al.   Oncotarget

Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma

(2015) Danielle M Lussier et al.   Journal for ImmunoTherapy of Cancer

Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2014)   ANNALS OF ONCOLOGY

Expression of programmed death 1 is correlated with progression of osteosarcoma

(2014) Wenjie Zheng et al.   APMIS

Recent advances in osteosarcoma

(2014) Sander M Botter et al.   CURRENT OPINION IN PHARMACOLOGY

Prognostic significance of HLA EMR8-5 immunohistochemically analyzed expression in osteosarcoma

(2014) Ola H Nada et al.   Diagnostic Pathology

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Tumor MHC Class I Expression Improves the Prognostic Value of T-cell Density in Resected Colorectal Liver Metastases

(2014) S. Turcotte et al.   Cancer Immunology Research

Programmed Cell Death Ligand 1 Expression in Osteosarcoma

(2014) J. K. Shen et al.   Cancer Immunology Research

Immunotherapy

(2012) Anne-Marie Cleton-Jansen et al.   OncoImmunology

Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion

(2011) R. D. Schreiber et al.   SCIENCE

Molecular mechanisms of MHC class I abnormalities and APM components in human tumors

(2008) Barbara Seliger   CANCER IMMUNOLOGY IMMUNOTHERAPY